EUCTR2005-004430-41-GB进行中（未招募）1 期
Effect of food on the pharmacokinetic profile of saquinavir at steady state in HIV-infected patients treated with saquinavir/ritonavir 1000/100 mg b.i.d. - Saquinavir food pharmacokinetic study
St Stephen's AIDS Trust0 个研究点目标入组 24 人开始时间: 2005年9月26日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1.The ability to understand and sign a written informed consent form, prior to participation in any screening procedures and must be willing to comply with all study requirements.
- •2.Male or non-pregnant, non-lactating females.
- •3.Between 18 to 65 years, inclusive.
- •4.Documented HIV-1 infection and plasma HIV RNA at screening visit below 50 copies/mL. (Note retesting of screening viral load is allowed).
- •5.Receiving a stable ARV regimen that includes saquinavir/ritonavir and 2 or more NRTIs for at least two weeks before the screening.
- •6.Agrees not to change saquinavir/ritonavir regimen from screening until end of the treatment period (except for the dose change in saquinavir/ritonavir as described in the Protocol), unless this is medically indicated as decided by the treating physician
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Any serious or active medical or psychiatric illness which, in the opinion of the investigator, would interfere with subject treatment, assessment, or compliance with the protocol. This would include any active clinically significant renal, cardiac, hepatic, pulmonary, vascular, metabolic disorders or malignancy.
- •2.Have a body mass index (BMI) >30
- •3.Presence of any current active AIDS defining illness (Category C conditions according to the CDC Classification System for HIV Infection 1993) with the following exceptions:
- •Stable cutaneous Kaposi’s Sarcoma
- •4.Clinically relevant alcohol or drug use (positive urine drug screen) or history of alcohol or drug use considered by the Investigator to be sufficient to hinder compliance with treatment, follow-up procedures or evaluation of adverse events. Smoking is permitted, but tobacco intake should remain consistent throughout the study.
- •5.Concurrent non-nucleoside reverse transcriptase inhibitor (NNRTI) use
- •6.Concurrent protease inhibitors apart from the use of ritonavir at doses less than or equal to 100 mg twice daily.
- •7.The use of disallowed concomitant therapy (See Concomitant Medication and treatment, section 4.4).
- •8.Females of childbearing potential without the use of effective non-hormonal birth control methods or not willing to continue practicing these birth control methods for at least 14 days after the end of the treatment period.
- •9.Previous allergy to any of the constituents of the pharmaceuticals administered in this trial.
- •10.Subjects with clinical or laboratory evidence of significantly decreased hepatic function.
研究者
相似试验
已完成
1 期
Effect of food on the pharmacokinetics ofonce-daily prolonged-release tacrolimusInteraction between food and tacrolimus.Healthy volunteersDRKS00012830niversitätsklinikum Heidelberg37
招募中
不适用
The effect of food on the pharmacokinetics of rosuvastatiKCT0000752Samsung Medical Center12
已完成
不适用
Pilot study of food effect on pharmacokinetics of STROMECTOL in scabies patients.scabiesJPRN-UMIN000006789aboratory of medical safety management, Tokyo University of Science12
已完成
1 期
The effect of food on the pharmacokinetcs, tolerability and pharmacodynamics of BNC210 in healthy male volunteersGeneralised Anxiety DisorderMental Health - AnxietyACTRN12610000442000Bionomics Limited4
已完成
Unknown
Pharmacokinetic study of food ingredientHealthy subjectsJPRN-UMIN000049201M&I Science CORP.5